

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Tolerx, Inc.	12/22/2011
RECEIVING PARTY DATA	
Name:	The Tolerx, Inc. Liquidating Trust
Street Address:	14114 Chinkapin Drive
City:	Rockville
State/Country:	MARYLAND
Postal Code:	20850
PROPERTY NUMBERS Total: 8	
Property Type	Number
Patent Number:	7541443
Patent Number:	7947272
Application Number:	12660881
Patent Number:	5690933
Patent Number:	6056956
Patent Number:	6767996
Patent Number:	5502167
Patent Number:	5670150
CORRESPONDENCE DATA	
Fax Number:	9739941744
Phone:	(973) 994-1700
Email:	jspeidel@carellabyrne.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Carella, Byrne, Cecchi, Olstein, Brody &
Address Line 1:	5 Becker Farm Road

CH \$320.00 7541443

Address Line 2: Raymond J. Lillie
Address Line 4: Roseland, NEW JERSEY 07068

ATTORNEY DOCKET NUMBER: 84468-1

NAME OF SUBMITTER: Raymond J. Lillie

Total Attachments: 4
source=tolerxassign#page1.tif
source=tolerxassign#page2.tif
source=tolerxassign#page3.tif
source=tolerxassign#page4.tif

PATENT ASSIGNMENT

THIS ASSIGNMENT, effective as of December 22, 2011, WITNESSETH:

WHEREAS, Tolerx, Inc., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 300 Technology Square, Cambridge, MA 02139 (hereinafter "Assignor") is the owner of a partial right, title, and interest in and to the United States Letters Patent and United States patent applications and the foreign patents and applications identified on Schedule A attached hereto, and the inventions claimed in the said identified patents and patent applications, and has rights, under one or more licenses (i.e., "license rights"), under the United States Letters Patent and United States patent applications, and the foreign patents and applications identified on Schedule B attached hereto, and the inventions claimed in said identified patents and patent applications (hereinafter "the Property"); and

WHEREAS, The Tolerx, Inc. Liquidating Trust, a liquidating trust organized and existing under the laws of the State of Delaware, having a place of business at 14114 Chinkapin Drive, Rockville, MD 20850 (hereinafter "Assignee") is desirous of acquiring the Assignor's right, title, and interest, and license rights in and to the Property.

NOW, THEREFORE, for the consideration of One Dollar (\$1.00) and for good and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby assign, sell, transfer, convey and grant Assignee, its successors and assigns, its right, title, and interest, and license rights in and to the Property, including the right to apply for, Letters Patent and certificates of invention in Assignee's name for the aforementioned inventions in the United States and all countries foreign thereto, and all reissues, extensions, renewals, divisions and continuations with respect to the Property, from the date hereof to the full end of the term or terms for which the Property may be issued, the same to be held and enjoyed by Assignee, its successors and assigns to the same extent that it would have been held and enjoyed by Assignor if this Assignment had not been made.

Assignor authorizes and requests the United States Patent and Trademark Office and corresponding foreign Patent Offices to issue all Letters Patent which may issue on a patent application

included in the Property to Assignee, its successors and assigns, in accordance with this Patent Assignment.

Assignor binds itself, as well as its successors, assigns and legal representatives to execute and deliver to Assignee, its successors and assigns, any further documents or instruments and do any and all further acts that may be necessary to vest in Assignee, its successors and assigns, the title herein conveyed, or intended so to be, and to the extent possible to enable such title to be recorded in the United States Patent Office and any corresponding foreign Patent Office.

Assignor further covenants, and agrees that it will at any time upon request communicate to Assignee, its successors and assigns, any facts pertinent to the validity or enforceability of the Property and the history thereof, known to Assignor or to its executors and administrators, and that Assignor will at Assignee's expense testify as to the same in any interference or to other litigation when requested to do so by Assignee, its successors or assigns.

IN WITNESS WHEREOF, the Assignor has herein caused these presents to be executed by a duly authorized corporate officer on this 22nd day of December, 2011.

Attest: _____

TOLERX, INC.

By: _____

Andrea J. Corcoran

Date: December 22, 2011

Title: General Counsel and Secretary

Schedule A

Patents and Applications Owned Partially by Tolerx

TRX1 Antibody and Uses Therefor

United States Patent No. 7,541,443
United States Patent No. 7,947,272
United States Patent Application Serial No. 12/660,881

Australian Patent No. 2002302848
Australian Patent No. 2004207839
Australian Patent Application No. 2008229990
Australian Patent Application No. 2009238366

Canadian Patent Application No. 2,450,700
Canadian Patent Application No. 2,514,580

European Patent No. 1,395,284 (granted in France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom)

European Patent Application No. 047060892
European Patent Application No. 080114432
European Patent Application No. 101828408

Japanese Patent No. 4,448,906
Japanese Patent Application No. 2006-503184

Schedule B

Patents and Applications Licensed to Tolernx

Use of Non-Depleting Anti-CD4 Antibodies in the Induction of Immunological Tolerance to an Antigen

United States Patent No. 5,690,933

United States Patent No. 6,056,956

Framework Mutated Antibodies and Their Preparation

United States Patent No. 6,767,996

Malaysian Patent No. 111682A

CDR Grafted Humanized Chimeric T-Cell Antibodies (CD2)

United States Patent No. 5,502,167

European Patent No. 667,902 (granted in

Austria (granted as Austrian Patent No. 234,923),
Belgium, Denmark, France, Germany (granted as German Patent No. 692329684), Ireland, Italy,
Luxembourg, Netherlands, Spain (granted as Spanish Patent No. 2,194,011), Sweden,
Switzerland, and United Kingdom).

Japanese Patent No. 3,339,637

Non-Depleting CD4- Specific Monoclonal Antibodies for the Treatment of Insulin-Dependent Diabetes Mellitus (IDDM)

U.S. Patent No. 5,670,150

DOCSLIB-#465828-v1